The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that features epidermal growth factor receptor (EGFR) exon 19 deletions or L858R substitution mutations. This approval targets patients whose disease has […]
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) mutations. This approval marks a significant advancement in the treatment landscape for patients with EGFR-mutated NSCLC, providing a […]
Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study, showcasing significant advances in treating non-small cell lung cancer (NSCLC). This data, involving both EGFR wild-type (EGFRwt) and mutated (EGFRmut) NSCLC cohorts, marks a pivotal step in leveraging the innate immune system to combat cancer effectively. Clinical […]
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from its WU-KONG1 Part B (WU-KONG1B) study of sunvozertinib, showcasing substantial efficacy in treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins). The findings were presented at the 2024 American Society of Clinical Oncology […]
Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for its lung cancer drug candidate, Oncoprex. Conducted at The University of Texas MD Anderson Cancer Center, the trial focuses on the investigational immunogene therapy drug in combination with the tyrosine kinase inhibitor erlotinib (Tarceva), targeting patients with […]